CytoDyn Announces FDA Clearance to Proceed with Phase 2 Study of Leronlimab (PRO 140) and Regorafenib as a Combination Therapy for Metastatic Colorectal Cancer
Stock Information for Cytodyn Inc
Loading
Please wait while we load your information from QuoteMedia.